Close
Close

Genentech, Inc. - Hemophilia A

Partner

Not provided

Rare Disease

Hemophilia A

Sponsor

Genentech, Inc.

Access Program Information

This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.

Contact
Locations
  • United States
  • Aurora, Colorado, United States
  • United States
  • Miami, Florida, United States
  • United States
  • Chicago, Illinois, United States
  • United States
  • New Orleans, Louisiana, United States
  • United States
  • Boston, Massachusetts, United States
  • United States
  • Minneapolis, Minnesota, United States
  • United States
  • Kansas City, Missouri, United States
  • United States
  • Newark, New Jersey, United States
  • United States
  • Columbus, Ohio, United States
  • United States
  • Oklahoma City, Oklahoma, United States
  • United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • United States
  • Salt Lake City, Utah, United States
  • United States
  • Seattle, Washington, United States

Free Newsletter